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Evaluation of a Program to Improve Diabetes Care
Through Intensified Care Management Activities and
Diabetes Medication Copayment Reduction
Stephen J. Kogut, PhD, MBA; Scott Johnson, PharmD, MS;
Tara Higgins, BS Pharm, CDOE; and Brian J. Quilliam, PhD

ABSTRACT
BACKGROUND: Medication copayment reduction can be integrated with disease management programs to incentivize patient engagement in chronic
care management. While disease management programs in diabetes have
been evaluated across a range of settings and designs, less is known
regarding the effectiveness of copayment reduction as a component of
disease management.
OBJECTIVE: To evaluate the short-term results of a diabetes-focused disease management program that included copayment reduction, care coordination, and patient goal setting, focusing on rates of evidence-based care
processes and all-cause pharmacy and health care costs.
METHODS: Blue Cross & Blue Shield of Rhode Island offered large employer
groups the opportunity to participate in a diabetes disease management
initiative that featured reduced copayments (from $7/$25/$40 for generic,
tier 2, and tier 3 drugs, respectively, to $0 for generic and $0-$2 for brand
drugs) for diabetes-related medications. In return for the copayment reduction, participants agreed to the following: (a) participate in care coordination with a case manager, (b) have an annual physical examination, (c) have
a hemoglobin A1c blood test at least twice annually, and (d) have a lowdensity lipoprotein cholesterol (LDL-C) test at least once annually. Patients
received personalized support provided by a registered nurse and dietician, disease-related education provided by nurses, and intensified case
management services, including working with a health coach to establish
healthy behavioral change goals. All study subjects were aged 18 years or
older and had at least 1 ICD-9-CM code for diabetes and at least 1 claim
for an antidiabetic drug during a 12-month measurement period, which was
each subject’s most recent 12-month period of continuous enrollment from
January 1, 2008, through May 31, 2010. Administrative claims data were
used to determine the percentage of intervention (participating) and nonintervention (nonparticipating) subjects from among all of the plan’s employer groups who received at least once-yearly monitoring of A1c, high-density
lipoprotein cholesterol (HDL-C), and LDL-C; medical attention (or drug
therapy) for nephropathy; and an eye examination. We conducted multivariate logistic regression analyses to assess the effect of the intervention and
other patient characteristics and comorbidities on rates of performance of
these care processes, aggregating the 5 processes of care into an “all or
none” single composite outcome. We also developed a propensity scoreweighted model to attempt to adjust for differences between the intervention and nonintervention groups resulting from the nonrandomized study
design. Additionally, we quantified average plan payments to providers less
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patient copayments (i.e., net plan cost) per patient per year (PPPY) for the
12-month follow-up period and compared these costs for the intervention
versus nonintervention groups.
RESULTS: The study sample consisted of 9,698 patients with diabetes; 649
(6.7%) of whom participated in the intervention. 9,049 (93.3%) patients
were identified by the insurer as patients with diabetes receiving usual
care. Patients in the intervention and nonintervention groups were similarly
likely to have all 5 recommended processes of care performed (40.1% vs.
38.9%, respectively, P = 0.543). Younger patients received all 5 recommended care processes less frequently than older patients (30.5%, 38.0%,
and 47.0% for ages 18-48 years, 49-59 years, and 60 years or older,
respectively, P < 0.001); in adjusted analyses, patients aged 60 years or
older were approximately twice as likely to receive all 5 care processes
compared with patients aged 18-48 years (odds ratio [OR] = 1.97, 95%
CI = 1.75-2.21). Users of oral antidiabetic monotherapy were least likely to
have these processes of care performed compared with users of multiple
oral therapies (OR = 1.23, 95% CI = 1.11-1.36) and insulin (OR = 1.59, 95%
CI = 1.41-1.78). PPPY prescription drug costs incurred by the plan were
greater for intervention than comparison patients (means [SDs] of $3,139
[$3,426 ] vs. $2,854 [$3,938], respectively, P < 0.001); and the genericdispensing ratio was slightly lower (means [SDs] of 62.1% [22.4%] and
65.4% [23.0%], respectively, P < 0.001). There were no significant differences between the intervention and comparison groups in mean [SD]
PPPY all-cause medical care costs ($7,475 [$17,601] vs. $8,577 [$22,972],
respectively, P = 0.213) or total all-cause costs ($10,613 [$18,590] vs.
$11,431 [$24,060], P = 0.666).
CONCLUSIONS: Patients participating in this incentive program featuring
diabetes medication copayment reduction and disease management components did not receive recommended care any more or less frequently
than other enrolled members with diabetes. Younger patients and those
utilizing oral antidiabetic monotherapy as their drug regimens were less
likely to have the recommended processes of care performed. While prescription drug expenditures incurred by the plan were greater for intervention patients, between-group differences in total costs for medications and
all-cause medical care were not statistically significant. Further follow-up
is required to determine the success of this program over the longer term
in promoting quality of care and achieving cost reductions and improved
health outcomes.
J Manag Care Pharm. 2012;18(4):297-310
Copyright © 2012, Academy of Managed Care Pharmacy. All rights reserved.
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What is already known about this subject

What this study adds (continued)

• Although diabetes management has improved during the past
decade, there is opportunity for improvement. The National
Committee on Quality Assurance (NCQA) Healthcare
Effectiveness Data and Information Set (2009) indicated that
approximately 89% of commercially insured patients with diabetes had hemoglobin A1c measured at least once yearly, while
rates for low-density lipoprotein cholesterol (LDL-C) screening
and monitoring for nephropathy were 85% and 82%, respectively. Lower rates were reported for the performance of diabetic
eye examinations (57%). The 2010 National Healthcare Quality
Report found that in 2007, 88% of patients with diabetes had A1c
measured, and 61% received eye examinations.
• The Medicare Health Support Pilot Program (2011), which randomized approximately 240,000 Medicare beneficiaries with
diabetes or heart failure to either standard care or a disease
management intervention employing remote call centers staffed
by nurses, found no significant between-group differences in
hospital admissions or overall costs of care.
• A cluster-randomized trial by Sönnichsen et al. (2010) evaluated
a disease management intervention comprising interdisciplinary
care, face-to-face physician and patient education, standardized
medication documentation, and shared physician-patient goal
setting. Compared with 840 study patients receiving usual care,
the 649 intervention patients more frequently had recommended
care performed (e.g., eye and foot examinations and A1c measurement) and experienced reductions in body mass index and blood
cholesterol. However, statistical analyses revealed no sustained
between-group differences in A1c reduction over time.
• Less is known about the outcomes of copayment reductions in
disease management programs. Gibson et al. (2011) described
the outcomes of copayment reduction for diabetes medications,
separately and when coupled with a disease management program. Among disease management participants, but not among
nonparticipants, drug copayment reductions were associated
with higher rates of completion of A1c, lipid testing, and urinalysis, and results were sustained over a 3-year follow-up period.
In a study of an initiative implemented by one large employer,
Chernew et al. (2008) found that copayment reductions from
$5/$25/$45 to $0/$12.50/$22.50 for generic, tier 2, and tier 3
medications, respectively, were associated with a 4.02 percentage
point increase in medication possession ratio (P < 0.001).

test: 86.7% vs. 89.8%, P = 0.014; A1c test: 92.3% vs. 94.1%,
P = 0.064; medical attention for nephropathy: 83.8% vs. 83.3%,
P = 0.726, respectively). Rates were lower overall for eye examinations, yet similar among intervention versus nonintervention
patients (51.2% vs. 48.0%, P = 0.114).
• The average 12-month per member all-cause plan cost for medications and medical care among intervention patients was similar
to cost for members with diabetes who did not participate in the
program ($10,613 vs. $11,430, respectively, P = 0.666). Average
all-cause medication cost was higher for intervention than comparison group patients ($3,139 vs. $2,854, respectively, P < 0.001)
and the average generic-dispensing ratio was lower (62.1% vs.
65.4%, respectively, P < 0.001).
• The odds of receiving all 5 recommended care processes were
twice as high for patients aged 60 years or older compared with
patients aged 18 to 48 years (odds ratio [OR] = 1.97, 95% CI = 1.752.21). Compared with users of oral monotherapy, odds were
23% higher for users of multiple oral therapies (OR = 1.23, 95%
CI = 1.11-1.36) and 59% higher for insulin users (OR = 1.59, 95%
CI = 1.41-1.78).

What this study adds
• Patients volunteering to participate in a diabetes-focused disease
management and copayment incentive program had generally
high rates of annual performance of 4 important elements of
diabetes care that were similar to those of the plan’s patients with
diabetes who did not participate in the program (high-density
lipoprotein cholesterol test: 85.7% vs. 89.7%, P = 0.001; LDL-C
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iabetes mellitus is a major burden on the U.S. health
care system. Estimates from the U.S. Centers for
Disease Control indicate that approximately 26 million
people in the United States are living with diabetes, including
7 million Americans who are undiagnosed, while nearly 2 million adults were newly diagnosed with diabetes during 2010.1 It
is estimated that 1 in 3 people in the United States will develop
diabetes during their lifetime.2 Diabetes is the sixth leading
cause of death in the United States, contributing to approximately 225,000 deaths yearly.3 In 2002, diabetes contributed to
16.9 million days of hospitalization and 62.6 million physician
office visits, and total average health care expenditures were
$13,243 for every person with diabetes compared with $5,642
for every person without diabetes, controlling for age and
other demographic characteristics.4 These figures underscore
why the health care system continues to devise and implement
interventions to manage the disease and reduce diabetesrelated complications and associated costs.
As a result of the high prevalence5 and cost burden6 associated with diabetes and its complications, managed care organizations are directing significant resources towards ensuring
that evidence-based care is routinely delivered to promote risk
reduction and avert untoward health outcomes. Quality of
care recommendations for diabetes supported by the American
Diabetes Association include the routine measurement of
glycosylated hemoglobin (A1c), blood lipids and renal function, and routine diabetic retinal examinations for preventing
disease complications.7 Poor glycemic control and dyslipidemia
are significant risk factors for coronary artery disease (CAD)
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in patients with diabetes. For example, using data from the
United Kingdom Prospective Diabetes Study to assess risk factors for CAD, Turner et al. (1998) reported a hazard ratio (HR)
of 2.26 for low-density lipoprotein cholesterol (LDL-C; 95%
confidence interval [CI] = 1.70-3.00); HR = 1.52 for A1c (95%
CI = 1.15-2.01); and HR = 0.55 for high-density lipoprotein cholesterol (HDL-C; 95% CI = 0.41-0.73), comparing patients categorized within the upper-third versus lowest-third levels.8 The
prevention of nephropathy and retinopathy is an additionally
important area of focus. According to data from the National
Health and Nutrition Examination Survey (NHANES IV),
approximately 40% of patients with type 2 diabetes have some
degree of chronic kidney disease, findings that underscore
the importance of early detection and intervention.9 Zhang
et al. (2010) determined the prevalence of retinopathy among
NHANES IV participants with diabetes receiving a medical
examination, finding that 4.4% had retinopathy classified as
being a threat to vision.10
Results from the 2009 National Committee on Quality
Assurance (NCQA) Healthcare Effectiveness Data and
Information Set (HEDIS) reveal a generally high level of performance of diabetes-related quality of care processes among
patients enrolled in commercial plans: approximately 89% of
patients with diabetes had their A1c measured at least once
yearly, while rates for LDL-C screening and monitoring for
nephropathy were 85% and 82%, respectively.11 Lower rates
were reported for the performance of diabetic eye examinations
(57%). These results are similar to the findings reported in the
2010 National Healthcare Quality Report, which revealed that
88% of patients with diabetes had their A1c measured in 2007,
while eye examinations were received by 61% of patients.12
These results also indicate opportunity for improving these
core measures of routine diabetes care.
Disease management approaches in diabetes have included
components such as enhanced patient education, improved
care coordination, increased involvement of pharmacists, and
the use of remote call centers for patient support. The Medicare
Health Support (MHS) Pilot Program, which is the largest evaluation of disease management delivered to older patients with
diabetes published to date, found that disease management
programs employing remote call centers staffed by nurses were
ineffective in decreasing hospital admissions or reducing overall costs of care.13 In the MHS, more than 240,000 patients with
diabetes or heart failure were randomized to either the disease
management intervention or standard care. Improvements
were noted for only 14 of 40 of the processes of care measured,
with only small percentage point changes observed.
A cluster-randomized trial conducted by Sönnichsen et al.
(2010) evaluated a disease management intervention comprising interdisciplinary care, face-to-face physician and patient
education, standardized medication documentation, and
shared physician-patient goal setting delivered to 649 Austrian
patients with diabetes.14 Compared with the 840 study patients
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receiving usual care, intervention patients more frequently had
recommended care performed (e.g., eye and foot examinations
and A1c measurement) and experienced reductions in body
mass index and blood cholesterol. A small improvement (0.13
percentage point) was observed in reduction of A1c among
intervention patients, yet the difference in A1c reduction
between intervention and control patients was not sustained
after statistical adjustment for cluster effects and status at
baseline.14 A randomized trial by Hogg et al. (2009) found that
Anticipatory and Preventive Team Care (APTCare) involving
nurse practitioners and pharmacists delivered to 120 patients
yielded improvements in guideline-based processes of care
across several conditions including diabetes.15 However, the
improvements in the diabetes-specific measures were not statistically significant nor were significant differences observed
in rates of hospitalization or patient quality of life between the
intervention and usual care groups.
Disease management programs including diabetes medication copayment reduction or waiver have been evaluated
as a means of improving diabetes care and reducing cost.
Noteworthy models include the Asheville Diabetes Care Project
(Asheville Project)16 and the subsequent Diabetes Ten City
Challenge.17 While the primary focus of the Asheville Project
was to apply pharmaceutical care services specific to diabetes
management, the initiative also offered participants copayment
waivers for diabetes medications and supplies. The evaluation
measures employed in the Asheville Project focused upon the
achievement of therapeutic goals; patients who did not have
A1c and lipid measurements performed were considered lost
to follow-up. Participants in the Asheville Project reported
that the medication copayment waiver was a highly important
factor in agreeing to participate in the program.18 Results of
the Diabetes Ten City Challenge included increases in rates
of performance of several diabetes-related processes of care,
including eye examinations (from 57% at baseline to 81%),
yearly A1c testing (54% to 97%), and yearly lipid profile tests
(51% to 92%), while average total health care costs per person
were reduced by $1,080 for the 1-year study period.17
However, the improvements in diabetes care and outcomes
reported in these 2 studies should be interpreted cautiously in
consideration of the nonexperimental designs employed and
the health status of study participants at baseline. Patients
participating in the Asheville Project were not randomized to
the intervention, and a majority (more than 61%) of patients
entered the study with poorly controlled diabetes (A1c level
exceeding 7%). In the Diabetes Ten City Challenge, patient
enrollment was voluntary, and the study employed a pre-post
design without a control group comparison. While improvements in rates of performance of diabetes-related care processes were substantial, it is uncertain if these improvements
differed from usual care patterns among the employers’ nonparticipating employees with diabetes.
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In the years following these 2 important studies, the value
of medication therapies has been a growing consideration in
formulary designs,19,20 and the results of comparative effectiveness research may yet support copayment variation based on
expected value for a particular patient’s clinical circumstance.21
Yet, there has been a paucity of research examining the effect
of copayment waiver or reduction on patient health outcomes,
quality of care, and cost.
Gibson et al. (2011) described the outcomes of a value-based
insurance design including copayment reduction for diabetes
medications, as evaluated separately and when coupled with a
disease management program.22 This was a voluntary program
offered by one large employer to all of its employees with diabetes. These researchers found that the intervention including
both the pharmacy copayment reduction and disease management components yielded higher rates of completion of A1c,
lipid testing, and urinalysis, compared with disease management alone. The results were sustained over a 3-year follow-up
period. Chernew et al. (2008)23 and Chang et al. (2010)24 also
reported improvements in diabetes medication adherence associated with copayment reduction or waiver, although neither of
these studies employed a randomized design, and in the study
by Chang et al., copayment reduction was not incorporated
within a defined disease management program.
In 2008, Blue Cross & Blue Shield of Rhode Island (RI) initiated an employer-based voluntary pilot program to improve
diabetes-related care. Our aim was to describe the association
of the program with the quality of care received, focusing
upon the performance of 5 diabetes-related processes of care:
annual LDL-C, HDL-C, and A1c testing; medical attention for
nephropathy; and eye examinations. We sought to determine if
patients participating in the program more frequently received
these processes of care during a 12-month period compared
with all other Blue Cross & Blue Shield of RI members with
diabetes who were not enrolled in the program. Between these
groups, we also compared the average per-member costs associated with the utilization of prescription drugs and medical
services.
■■ Methods
Design and Intervention
We employed a retrospective, cross-sectional design, using
electronic claims data to describe patients’ health service
utilization and associated cost during a 12-month time frame
between January 1, 2008, and May 31, 2010. All patients had
at least 12 continuous months of enrollment and were at least
18 years of age. The data sources used in this analysis included
medical, pharmacy, and enrollment data files, providing demographic information, medical diagnoses, health care procedures, medication dispensings, and hospital discharge records.
These data included associated costs where applicable.
The main elements of the program included disease
300 Journal of Managed Care Pharmacy
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education, counseling, and close oversight provided by
assigned nurse case managers and copayment reductions for
diabetes-related medications. Specifically, medication copayments for intervention members were reduced to either $2.00
for brand name medications and $0 (zero) for generic medications, or to a $0 copayment for both brand and generic antidiabetic medications, depending upon the account. The 3-tier
pharmacy benefit design for members not participating in the
program remained as $7/$25/$40 for generic, tier 2, and tier 3
medications, respectively. The program required that participants agree to the following: (a) participate in care coordination
with their case managers, (b) have an annual physical exam,
(c) have an A1c blood test at least twice a year, and (d) have
an LDL-C test performed at least once per year. Additionally,
patients received personalized support provided by a registered
nurse and dietician, which included working to achieve healthrelated goals. Patients also received disease-related education
provided by nurses and intensified case management services,
including working with a health coach to establish healthy
behavioral change goals. Members also completed a contract
that pledged their agreement to remain engaged in care and to
receive recommended tests and health exams. Participants were
informed that the copayment reduction would be rescinded if
they did not receive recommended tests and participate in
care coordination. Patients not participating in the program
received usual care, which included the plan’s usual disease
management components such as the provision of educational
materials and case management following a hospital visit, but
without personalized goal setting or copayment reductions.
The diabetes care management activities and diabetes medication copayment reduction program (i.e., the “intervention”)
was offered to the plan’s larger employer groups with 1,000
or more employees. Five of these groups agreed to participate.
Patient recruitment was performed by Blue Cross & Blue Shield
of RI, which had sole responsibility for identifying members
with diabetes in the participating employer groups; invitations
to participate in the program were mailed by the health plan
to these patients’ homes. The mailings were followed by a telephone voice reminder message sent 2 weeks later.
The intervention group for the study comprised those members who were offered the program and agreed to participate
through May 31, 2010. For these patients, the study time frame
consisted of the most recent 12 months of participation in the
program. The comparison group comprised all other members identified by the plan as having diabetes during the time
frame, including those members from both the large employer
groups from which the intervention patients were recruited
and from among all of the plan’s other groups. For the comparison cohort, the most recent 12 months of continuous enrollment comprised the study time frame. All patients in both
groups received a dispensing for either an oral or injectable
medication for diabetes during the 12-month study time
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FIGURE 1

Study Inclusion and Exclusion Criteria
Insurer data extraction: Intervention participants and other members having diabetes
N = 21,153

843 agreed to participate in the intervention

20,310 nonintervention patientsa

Continuous enrollment
at least 12 months between
January 1, 2008, and
May 31, 2010 (exclude 46)

Continuous enrollment
at least 12 months between
January 1, 2008, and
May 31, 2010 (exclude 1,818)
797

18,492

Must be aged 18 years or
older (exclude 12)

Must be aged 18 years or
older (exclude 172)
785

18,320

Diabetes diagnosis verified
by ICD-9-CM code and Rx
use (exclude 136)b

Diabetes diagnosis verified
by ICD-9-CM code and Rx
use (exclude 9,245)b
649

9,075

No diagnosis of polycystic
ovary syndrome (exclude 0)

No diagnosis of polycystic
ovary syndrome (exclude 26)
649

9,049

a Nonintervention

patients include those who were offered the intervention program through their employers and patients identified as having diabetes by other employer
groups that did not offer the intervention.
bDiabetes diagnosis verified by presence of at least 1 defining ICD-9-CM code and at least 1 medication for diabetes dispensed during the 12-month measurement period
(Appendix).
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; Rx = prescription drug.

frame and had a diagnosis of diabetes documented during this
12-month period. We excluded patients who had a primary or
secondary diagnosis of polycystic ovary syndrome, for which
metformin may be prescribed. The flowchart in Figure 1 presents an overview of the study inclusion criteria and sequence.
Study Outcomes and Statistical Analyses
Our main objectives were to compare (a) rates of performance
of recommended diabetes-related care processes between
the intervention and nonintervention groups and (b) allcause pharmacy and medical care costs between groups. We
determined the percentages of patients who received at least
once-yearly monitoring of A1c, HDL-C, LDL-C, and medical
attention for nephropathy, which included evidence of renal
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function monitoring, a diagnosis of nephropathy, or use of
an angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker (at least 1 pharmacy claim during the measurement period). We also determined if patients received a
dilated eye exam during this time span.
We created an “all or none” single composite outcome
comprising all these aspects of recommended care. Our measurement specifications were based on the 2009 HEDIS diagnosis and procedure code listings,25 with the exception of eye
examinations; due to our 12-month measurement time frame
we were unable give credit for negative retinal exam results
obtained in the prior year, as the HEDIS methodology allows.
Annual HDL-C monitoring is not included in the HEDIS
comprehensive diabetes care measure set. Our measure was
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TABLE 1

Variable
Age, years
Mean [SD] age

Selected Characteristics of Patients
Participating in the Diabetes
Incentive Program and Patients
in the Comparison Group
(Intervention vs. Nonintervention)
Intervention
(n = 649)
53.4 [10.72]
%
(n)
27.0 (175)
43.5 (282)
29.6 (192)

Nonintervention
(n = 9,049)
54.2 [9.68]
%
(n)
24.8 (2,243)
43.7 (3,957)
31.5 (2,849)

P Valuea
< 0.001

18 to 48
0.235
49 to 59
0.922
60 or older
0.335
Gender
Male
61.3 (398)
0.798
60.7 (5,496)
Female
38.7 (251)
39.3 (3,553)
0.798
Diabetes medication useb
Oral monotherapy
25.4
(165)
30.0 (2,713)
0.016
(no insulin)
Multiple oral therapy
43.6 (283)
44.3 (4,005)
0.770
(no insulin)
Any insulin
31.0 (201)
25.8 (2,331)
0.004
Comorbidityc
Asthma
5.5
(36)
7.5
(681)
0.074
COPD
1.1
(244)
0.017
(7)
2.7
CAD
11.9
(77)
16.5 (1,491)
0.002
CHF
4.0
(26)
4.3
(392)
0.774
Mental health diagnosis
8.9
(58)
10.0 (908)
0.408
Number of unique medications utilized during
the 12-month follow-up measurement periodd
Mean [SD] number
12.2
[7.5]
12.9
[7.6]
0.032
%
(n)
%
(n)
0-5
13.7
(89)
12.9 (1,165)
0.579
31.3 (2,833)
6-10
35.7 (232)
0.021
11-20
37.6 (244)
42.1 (3,812)
0.027
21 or more
12.9
(84)
13.7 (1,239)
0.632
a P values determined from Pearson chi-square tests for all categorical comparisons
and t-tests for independent samples for number of unique medications used and age.
bMeasured during the 12-month follow-up period.
cDefined as at least 1 relevant confirming diagnosis or procedure code (Appendix)
during the 12-month follow-up measurement period.
dUnique chemical entity regardless of dosage form or strength.
CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic
obstructive pulmonary disease; SD = standard deviation.

calculated using the Current Procedural Terminology (CPT)
codes for lipid panel and HDL-C testing as acceptable numerator qualifiers. The Appendix presents a listing of International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) and CPT codes used in identifying diagnoses and
processes of care.
In addition to comparing rates of these processes of care
between groups, the intervention and nonintervention groups
were compared according to age, gender, type of diabetes
medication used, and comorbidities. Most of the patients
302 Journal of Managed Care Pharmacy
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enrolled by this commercial insurer were middle-aged, nonelderly working adults and their family members. We created age categories that roughly approximated tertiles of the
distribution, while also maintaining at least a 10-year range
for the middle strata. Medication burden was determined
according to the number of unique medications utilized during the 12-month study time period, identified via National
Drug Code (NDC) numbers. This variable represented the sum
of unique medications utilized during the 12-month study
period, counting each chemical entity only once, regardless
of the number of dispensings or the dosage form or strength.
The type of diabetes medication regimen used during the 12month period was classified as follows: (a) oral monotherapy
without insulin use; (b) multiple oral therapy without insulin
use; or (c) any insulin use, with or without concomitant oral
medication use, also identified using product NDC numbers.
We also identified the following comorbidities via relevant
ICD-9-CM codes (appearing at least once during the 12-month
time frame): asthma, chronic obstructive pulmonary disease
(COPD), CAD, heart failure, and a mental health condition,
which included the diagnoses of depression, bipolar disorder,
and schizophrenia.
Rates of performance were determined for each of the
diabetes-related processes of care and for the aggregated composite measure, and these rates were stratified by group status
and according to the covariates identified above. Pearson chisquare tests were applied to determine the statistical significance of differences in these rates and also to assess differences
in patient characteristics and the presence of comorbidities
between the intervention and nonintervention groups.
A multivariate logistic model was developed to determine
the effect of the intervention on the outcome of the “all or
none” measure, defined as having all of the measured processes
of care performed during the 12-month period. The model
was created using a manual backward stepwise process. The
log-likelihood test was used to assess the multivariate model
at each step, removing least statistically significant covariates
with each iteration and evaluating differences between full and
reduced models for statistical significance (P < 0.05). Gender
and age remained in the model throughout. The HosmerLemeshow goodness-of-fit test was used to assess the calibration of the final model. The measure of effect was presented as
an odds ratio (OR) with corresponding 95% CIs.
To mitigate bias resulting from the nonrandomized design,
an inverse propensity score-weighted model was also utilized
to adjust for the likelihood of intervention group inclusion. A
2-stage propensity score approach was applied as described by
D’Agostino (1998),26 which attempted to account for differences
in diabetes severity and comorbidities between groups, recognizing that volunteers for the diabetes management program
may have differed in health status from the plan members with
diabetes who did not participate in the intervention. The first
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TABLE 2

Frequency and Percentage of Patients with Diabetes Receiving
Recommended Care by Group Status and Other Patient Characteristicsa
HDL-C Test
%
(n)

Group
Intervention (n = 649)
Usual care (n = 9,049)
Age, years
18-48 (n = 2,418)
49-59 (n = 4,239)
60 and older (n = 3,041)
Gender
Male (n = 5,894)
Female (n = 3,804)
Diabetes medication use
Oral monotherapy
(n = 2,878)
Multiple oral therapy
(n = 4,288)
Any insulin (n = 2,532)

LDL-C Test
%
(n)

A1c Test
%
(n)

85.7
(556)
89.7
(8,120)
P = 0.001

86.7
(563)
89.8
(8,125)
P = 0.014

92.3
(599)
94.1
(8,514)
P = 0.064

85.2
(2,061)
90.8
(3,849)
91.0
(2,766)
P < 0.001

(2,060)
85.2
91.1
(3,860)
91.0
(2,768)
P < 0.001

89.9
(5,301)
88.7
(3,375)
P = 0.057
88.4
91.4

Medical Attention
for Nephropathyb
%
(n)

Eye Exam
%
(n)

All Performed
%
(n)

83.8
(544)
83.3
(7,537)
P = 0.726

51.2
(332)
48.0
(4,339)
P = 0.114

40.1
(260)
38.9
(3,516)
P = 0.543

(2,223)
91.9
94.6
(4,010)
94.7
(2,880)
P < 0.001

77.3
(1,868)
83.7
(3,549)
87.6
(2,664)
P < 0.001

41.1
(995)
46.8
(1,982)
55.7
(1,694)
P < 0.001

30.5
(738)
38.0
(1,609)
47.0
(1,429)
P < 0.001

90.1
(5,310)
88.8
(3,378)
P = 0.042

94.0
(5,541)
93.9
(3,572)
P = 0.825

83.6
(4,929)
82.9
(3,152)
P = 0.322

46.7
(2,751)
50.5
(1,920)
P< 0.001

38.0
(2,240)
40.4
(1,536)
P = 0.019

(2,543)

88.3

(2,541)

91.9

(2,644)

76.3

(2,195)

44.3

(1,274)

32.5

(936)

(3,920)

91.6

(3,927)

95.2

(4,081)

85.3

(3,657)

48.1

(2,063)

39.7

(1,703)

(2,222)
(2,220)
(2,388)
88.0
52.7
44.9
87.8
87.7
94.3
(2,229)
(1,334)
(1,137)
P < 0.001
P < 0.001
P< 0.001
P < 0.001
P < 0.001
P < 0.001
a Between-group differences comparing intervention versus comparison group patients were assessed using Pearson chi-square tests.
bMedical attention for nephropathy includes use of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker drug or documentation of a range of
procedures that indicate provider attention to renal function.
A1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol.

stage of this approach aims to predict treatment group (i.e.,
intervention vs. nonintervention status) according to available
covariates. Variables assessed for incorporation into the propensity score included the type of diabetes medication utilized,
the comorbidities identified above, and the number of unique
medications utilized during the study time frame. Gender and
age remained in the model throughout, while other variables
were included if they were significant (P < 0.05) in building a
fitted multiple logistic regression model having an outcome
variable representing intervention group status. A correlation
matrix was used to identify the presence of multicollinearity,
and potential interactions between variables were explored.
In the second stage, the inverse propensity-score weight was
incorporated in a model predicting the diabetes processes of
care composite measure and including intervention group status as a weight-adjusted predictor.
Additionally, we calculated the 12-month costs of all-cause
medical care, pharmacy, and total health expenditures and
compared these costs for the intervention versus nonintervention groups. The Wilcoxon rank-sum (Mann-Whitney U) test
was used to evaluate differences between cost values. For all
analyses, we assumed an a priori significance level of P < 0.05
(2-sided). Data analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC).
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■■ Results
The insurer identified 21,153 patients with diabetes, 843 of
whom agreed to participate in the diabetes incentive program;
20,310 were members identified as having diabetes using algorithms employed by the plan but did not participate in the program. Approximately 5.5% of intervention patients and 9.0% of
nonintervention patients were excluded after application of the
continuous enrollment criterion. Among those enrolled for at
least 12 months, 12 intervention patients and 172 nonintervention patients were less than 18 years of age and were excluded.
We required that patients had at least 1 diagnosis of diabetes
and at least 1 dispensing of an antidiabetic medication during
the 12-month period. This criterion resulted in the additional
exclusion of 136 intervention and 9,245 nonintervention
patients. After excluding 26 patients from the nonintervention
group with a diagnosis of polycystic ovary disease, the final
study sample consisted of 9,698 patients with diabetes, 649
of (6.7%) of whom were participants in the intervention. No
intervention patients withdrew from the program during the
study time frame.
The mean (standard deviation [SD]) ages of patients in the
intervention and nonintervention groups were similar (53
[10.7] vs. 54 [9.7] years, respectively), as were the percentages
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TABLE 3

Multivariate Logistic Regression
Model:a Patient Covariates and
Intervention Group Status as
Predictors of Receiving All DiabetesRelated Processes of Care

Beta
Standard
Odds Ratio
Characteristic (n)
Coefficient
Error
(95% CI)
Group
Usual care (9,049)
Reference
Intervention (649)
0.0588
0.0847
1.061 (0.898-1.252)
Age, years
18-48 (2,418)
Reference
49-59 (4,239)
0.3181
0.0557
1.375 (1.233-1.533)
60 and older (3,041)
0.6759
0.0602
1.966 (1.747-2.212)
Gender
Female (3,804)
Reference
Male (5,894)
-0.0678
0.0446
0.934 (0.856-1.020)
Diabetes medication use
Oral monotherapy
Reference
(2,878)
Multiple oral therapy
0.2064
0.0525
1.229 (1.109-1.363)
(4,288)
Any insulin (2,532)
0.4621
0.0592
1.587 (1.414-1.783)
Comorbidity
1.0
Referenceb
Asthma (717)
-0.1176
0.0836
0.889 (0.755-1.047)
CAD (1,568)
0.0393
0.0620
1.040 (0.921-1.174)
CHF (418)
0.0178
0.1086
0.982 (0.794-1.216)
COPD (251)
-0.2410
0.1366
0.786 (0.601-1.027)
Mental health
-0.0818
0.0730
0.921 (0.799-1.063)
diagnosis (966)
Number of unique medications utilized
during the 12-month follow-up period
0-5 (1,254)
Reference
6-10 (3,065)
0.3229
0.0759
1.381 (1.190-1.603)
11-20 (4,056)
0.6217
0.0750
1.862 (1.607-2.157)
21 or more (1,323)
0.7000
0.0930
2.014 (1.678-2.417)
aC-statistic = 0.60.
bReference group is the absence of the particular comorbidity.
CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence
interval; COPD = chronic obstructive pulmonary disease.

of patients within each age stratum among these groups (Table
1). Males represented 61% of both the intervention and nonintervention groups. A higher percentage of patients in the intervention group were insulin users (31.0% vs. 25.8%, P = 0.004),
while in the nonintervention group a higher percentage of
patients were users of oral antidiabetic monotherapy (30.0% vs.
25.4%, P = 0.016). Comorbidities, identified by relevant diagnosis codes documented during the 12-month period, were more
frequent among nonintervention patients than intervention
patients, with statistically significant differences observed for
the prevalence of COPD (2.7% vs. 1.1%, respectively, P = 0.017)
and CAD (16.5% vs. 11.9%, P = 0.002). The mean number of
unique medications utilized per patient during the 12-month
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period was 12.2 for the intervention group compared with 12.9
for the nonintervention group (P = 0.032).
Patients in the intervention group were as likely as nonintervention patients to have all of the recommended processes
of care performed (40.1% vs. 38.9%, respectively, P = 0.543;
Table 2). Among all processes of care, annual A1c testing was
performed with the greatest frequency (92.3% of patients in
the intervention group; 94.1% of nonparticipating patients,
P = 0.064). Patients in the intervention group had lipid monitoring tests performed slightly less frequently than nonintervention patients (HDL-C testing: intervention group 85.7%
vs. nonintervention group 89.7%, P = 0.001; LDL-C testing:
intervention group 86.7% vs. nonintervention group 89.8%,
P = 0.014). Rates of renal function testing (or use of a renalprotective medication) were approximately the same between
groups (intervention group 83.8% vs. nonintervention group
83.3%, P = 0.726). The percentage of patients who received an
eye examination during the 12-month period was the lowest of
all measures, with 51.2% of intervention patients having documentation of an eye exam during the period, compared with
48.0% of nonintervention patients (P = 0.114 between groups).
Younger patients received all 5 of the recommended care
processes less frequently than older patients (30.5%, 38.0%,
and 47.0% for patients aged 18-48 years, 49-59 years, and 60
years or older, respectively, P < 0.001). Females had all recommended process of care performed more frequently than males
(40.4% vs. 38.0%, P = 0.019), as did patients who were utilizing
insulin (rate among patients with insulin use: 44.9% compared
with 39.7% and 32.5% for patients using multiple oral therapy
and oral monotherapy, respectively, P < 0.001).
Table 3 presents the result of the multivariate logistic
regression analysis including all covariates and intervention
group status as a predictor of receiving the diabetes-related
processes of care prior to adjustment using propensity scores.
In this model, the OR for intervention group status adjusted
for covariates was 1.06 (95% CI = 0.90-1.25), indicating that
intervention patients were not more likely to have the diabetesrelated processes of care performed compared with the nonintervention group.
The likelihood of having the processes of care performed
increased with age, as patients aged 49-59 years were 38%
more likely to receive recommended care compared with
patients aged 18-48 years (OR = 1.38, 95% CI = 1.23-1.53),
while patients aged 60 years or older were approximately
twice as likely to receive recommended care compared with
the youngest age group (OR = 1.97, 95% CI = 1.75-2.21).
Users of multiple oral antidiabetic therapies were 23% more
likely to have the processes of care performed compared
with users of oral antidiabetic monotherapy (OR = 1.23, 95%
CI = 1.11-1.36), and patients who utilized insulin at any time
during the measurement period were 59% more likely than
users of oral monotherapy to receive these processes of care
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TABLE 4

Propensity-Score Adjusted Odds
Ratio for Receiving All DiabetesRelated Processes of Care for
Program Participants (Intervention)
Relative to Other Plan Members
with Diabetes (Nonintervention)a

Group
Nonintervention (n = 9,049)
Intervention (n = 649)

Beta
Coefficient

Standard
Error

0.0895

0.0293

Odds Ratio
(95% CI)

Reference
1.094
(1.033-1.158)
aVariables represented in the propensity score include age category, gender,
asthma, COPD, the number of unique medications used, and the type of diabetes
medication regimen utilized (oral monotherapy, multiple oral therapy, or any
insulin use). C-statistic = 0.61.
CI = confidence interval; COPD = chronic obstructive pulmonary disease.

FIGURE 2
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Cost
Cost
(P = 0.341)
(P < 0.001)
(P = 0.213)
Intervention

(OR=1.59, 95% CI = 1.41-1.78). The likelihood of having the
processes of care performed increased with each category of
the number of unique medications used during the period,
with patients utilizing 21 or more unique medications being
most likely to receive the processes of care compared with
patients utilizing 5 or fewer medications during the period
(OR = 2.01, 95% CI = 1.68-2.42). Neither gender nor comorbidity status was associated with differences in the likelihood of
receiving the processes of care.
The multivariate model incorporating the propensity-score
weights included the intervention status variable and the predictors determined to be statistically significant in constructing the propensity-score weighted model. These included age
category, gender, the type of diabetes medication utilized, the
comorbidities of asthma and COPD, and the number of unique
medications used during the period. The propensity scoreadjusted model (Table 4) indicated that intervention group
status was associated with a small yet statistically significant
increase in the likelihood of receiving all of the recommended
care processes during the 12-month time frame (adjusted
OR = 1.09, 95% CI = 1.03-1.16).
We calculated mean per-patient all-cause health care costs
accrued during the 12-month study period, categorized as
medical care cost; prescription drug cost (for all drugs, not just
diabetes drugs); and total costs, which represented the sum of
medical and prescription drug costs (Figure 2). Prescription
drug costs incurred by the payer over the 12-month period
were greater for the intervention group than for nonparticipating patients ($3,139 vs. $2,854, respectively, P < 0.001). The
average per-patient pharmacy copayment amounts for all drugs
during the measurement period were $542 for intervention
patients and $545 for nonintervention patients (P = 0.341). The
average per-patient 12-month all-cause medical care costs were
lower for intervention patients; however, this difference in cost
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Average
Total Net
Cost
(P = 0.666)

Nonintervention

Allowed Pharmacy Pharmacy
Pharmacy Copayment Net Plan
Charge ($)
($)
Cost ($)a
Mean [SD]
3,681
542
3,139
inter[3,755]
[554]
[3,426]
vention
Mean [SD]
3,399
545
2,854
noninter[3,802]
[457]
[3,938]
vention
a Net plan cost after subtraction of patient cost share.
SD = standard deviation.

Medical
Net Plan
Cost ($)a
7,475
[17,601]

Total
Pharmacy
and
Medical
Net Plan
Cost ($)a
10,613
[18,590]

8,577
[22,972]

11,430
[24,060]

was not statistically significant ($7,475 vs. $8,577, respectively,
P = 0.213). Differences in mean per-patient total costs incurred
between the intervention and nonintervention groups were
also not statistically significant ($10,614 vs. $11,431, respectively, P = 0.666).
■■ Discussion
This study evaluated the results of a multifaceted approach
implemented by a commercial health insurer designed to
enhance diabetes management by providing patients with
intensified oversight and counseling as provided by nurse case
managers, coupled with reduced copayments for diabetesrelated medications as an incentive for participating in the
intervention including care coordination and agreeing to
receive recommended tests. The evaluation of this program
focused upon determining rates of performance of 5 recommended care processes and calculating costs of medical care
and prescription drugs used during a 12-month period.
As we were interested in evaluating the program during
its initial phase, our approach was to compare results among
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intervention patients with usual care, by forming a comparison
group comprising plan members with diabetes who did not
participate in the intervention. This approach introduced the
possibility of selection bias, as those agreeing to participate in
the program may have differed in important ways from nonparticipating members. For example, patients volunteering to
participate in the program may have been more inclined than
nonvolunteering patients to comply with blood testing for
cholesterol monitoring and instructions for glycemic control.
While the intervention patients were similar to patients in the
comparison group with respect to age distribution and gender,
they also utilized insulin more frequently and had a lesser
prevalence of COPD (1.1% vs. 2.7%, respectively, P = 0.017) and
CAD (11.9% vs. 16.5%, P = 0.002). These differences suggest
that the intervention group in general had a lesser comorbidity burden; yet, they may have had greater diabetes severity,
as indicated by the larger percentage of patients with insulin
dependence among intervention patients compared with nonintervention patients (31.0% vs. 25.8%, respectively, P = 0.004).
We attempted to control for the possibility of selection
bias through the use of a propensity score-weighted model, as
derived from a separate multivariate model that determined
significant predictors of intervention group status. The results
of this model were consistent with the findings of the bivariate analyses, which found that intervention group members
received these processes of care at a rate similar to that of
patients who did not participate in the intervention (40.1%
vs. 38.9%, respectively). In the multivariate logistic regression
model including all covariates, intervention group status was
not predictive of higher rates of performance of the recommended care processes. When assessed using a multivariate
model adjusted by propensity score, we found that members
enrolled in the program were slightly more likely to have all
of the recommended processes of care performed during the
measurement period compared with members not enrolled in
the program (OR = 1.09, 95% CI = 1.03-1.16).
While this model indicated a small increase in the likelihood of receiving all tests among intervention members, this
finding was likely driven by the between-group difference in
the rate of one particular test—eye examination rates (51.2%
intervention vs. 48.0% nonintervention, P = 0.114)—as rates of
LDL-C and HDL-C testing were slightly lower among intervention patients. In sum, our results indicate that no meaningful
difference existed between the intervention and nonintervention groups with regard to performance of the processes of care
measured.
Our methodological approach did not permit randomization of patients to the intervention; thus, our findings may have
been influenced by between-group differences in the burden
of disease and associated intensity of clinical management.
Our analyses revealed that the intervention group patients
were healthier than nonintervention patients during the study
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period, as measured by the prevalence of comorbidities and
the number of medications utilized. This difference may have
yielded closer oversight, more frequent provider contact,
and perhaps more aggressive monitoring for nonintervention
patients than for the relatively healthier patients in the intervention group. Another proxy for disease burden is the number
of unique medications utilized during the study time frame.
The patients in the intervention group were less frequently
categorized as using more than 10 medications, a finding that
further suggests that intervention members were healthier and
perhaps less intensely followed by care providers.
Our analyses identified several factors that were associated
with increased rates of performance of recommended care.
Age was a most significant predictor, as patients aged 60 years
or older were nearly twice as likely as patients aged 18 to 48
years to receive these processes of care. Users of antidiabetic
monotherapy and patients utilizing 5 or fewer different medications during the period were also less likely to have all of the
processes of care performed. While the margin of improvement
for the rates of performance of these processes care was greatest among younger patients and patients utilizing antidiabetic
monotherapy (compared with users of combination therapies
or insulin), further research is necessary to determine how
these subgroups specifically may respond to diabetes disease
management programs.
For comparison, we contrasted the rates observed in the
present study with the NCQA HEDIS benchmarks described
earlier.11 While we also included HDL-C monitoring in our
evaluation, this measure is not included within HEDIS, yet
is recommended by the American Diabetes Association. We
assumed that HEDIS rates for HDL-C screening would be
similar to HEDIS rates for LDL-C screening because both procedures are usually obtained with the same test. In contrasting
our intervention sample’s rates with those published by the
NCQA representing commercial insurers overall, we found
intervention patients to have slightly higher rates for yearly
A1c testing (92.3% vs. 89% for HEDIS), LDL-C testing (86.7%
vs. 84.8% for HEDIS), and medical attention for nephropathy
(83.8% vs. 82.4% for HEDIS). The percentage of members having a yearly eye examination was slightly lower in our intervention sample, with a rate of 51.2% versus 56.5% for HEDIS.
Among nonintervention patients in our sample, rates were
similar to those of intervention patients and, in fact, higher
for lipid measurements. Thus, performance rates for these
diabetes-related processes of care among both intervention and
nonintervention patients were high, reflecting previous and/
or existing standard disease management programs provided
to all members having diabetes. As such, the opportunity for
improvement resulting from this diabetes incentive program
may have been limited given the high baseline rates for most
of these measures.
An additional aim of this study was to determine whether
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the diabetes incentive program was associated with differences
in the costs of medical care and prescription drug utilization.
While pharmacy costs were greater among the intervention
group members, neither annual per-member medical costs
nor total costs differed in statistical significance. The difference in average per-patient overall medical care cost during
the period was $1,102, with the intervention patients incurring less spending. This finding may reflect the difference in
comorbidity prevalence between the intervention and nonintervention groups yet also was influenced by outlier patients
having extremely higher costs, as indicated by the difference
in the range of costs between groups (intervention patients
$43.9 to $199,694, SD = $17,601; nonintervention patients $0 to
$514,394, SD = $22,972). The outlier values would not dramatically influence the nonparametric statistical test applied, which
explains the lack of statistical significance for the difference
in medical care cost experienced between the groups. Further
evaluation of this program over time will be informative in
determining if cost reduction among intervention participants
is achieved over the longer term.
Intervention participants incurred higher expenditures for
prescription drug utilization compared with nonintervention
patients. This finding aligned with program expectations, given
the expected increased cost borne by the plan for the reduced
copayments for antidiabetic medications among intervention
members. Yet further analyses revealed that dispensings for
lower-cost generic medications were more frequent among
nonintervention members. The mean (SD) generic dispensing
ratio for all drugs (not just diabetes drugs) was 62.1% (22.4%)
among intervention patients compared with 65.4% (23.0%)
among nonintervention patients (P < 0.001, t-test, 2 sided). Due
to the limitations of our observational study design, we were
unable to determine the frequency of dispensing of generic
medications among those patients who were offered the program but declined to participate, which would enable a better
understanding of the relative value of copayment reduction as
perceived by patients using brand-name medication. Further
research examining the effects of copayment reduction as a
component of disease management in diabetes is warranted,
particularly considering that the value of medication therapies
is likely to be an increasingly important aspect of formulary
designs.
Limitations
Several limitations of this study should be recognized. First
and most importantly, we were unable to make comparisons
with prior periods to enable a pre-intervention versus postintervention analysis. The intervention may have provided
greater gains in performance rates or greater reductions in cost
from the previous year for those participating in the program,
yet we were unable to measure this possible effect. Also, given
the brief 12-month measurement time frame, we were unable
to determine the temporal relationships between variables. For
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example, a member could have been diagnosed with asthma
on the last day of the 12-month period and would have been
classified as having asthma for the entire study period.
Second, we evaluated all-cause costs but did not examine
diabetes-related costs specifically. We sought to determine the
overall cost impact associated with this disease management
program, which included components potentially affecting
expenditures for both diabetes and other health conditions,
such as cardiovascular and renal disease. Additionally, we
believed that reductions in diabetes-related costs would be
more likely than reductions in all-cause costs to occur after the
end of the 12-month measurement period. Nevertheless, there
may have been a significant impact of this disease management
program on diabetes-related costs in particular that was not
identified.
Third, we did not evaluate patient adherence to antidiabetic
medications. While it was envisioned that copayment reduction might promote medication adherence, the copayment
incentive was primarily designed to encourage patient interest and involvement in the disease management program to
enhance the quality of care overall, as assessed according to the
diabetes-related care processes evaluated in this study. To participate in the program and qualify for the copayment reduction, patients agreed to have an annual physical examination,
have A1c and cholesterol testing performed at recommended
intervals, and work with a care coordinator. Patients were not
required to achieve a particular level of medication adherence.
Thus, we focused our evaluation on the program components
described in the patient pledge.
Fourth, the all-or-none approach to the composite measure,
which represented whether all of the processes of care were
performed, could have missed overall better care. For example,
receipt of 4 of 5 measures and receipt of 0 of 5 measures were
both classified as failing to receive all recommended care.
However, it was evident from the rates observed for each specific measure that the processes of care were performed with
similar frequency for both the intervention and nonintervention members. Another important limitation pertains to the
lack of data available to identify the achievement of therapeutic
goals. We determined only whether a test was performed; we
were unable to determine the percentage of members who had
their blood glucose and lipid levels reduced to recommended
goals. Patients could have had all tests performed but still have
values representing high risk of diabetic complications.
A fifth limitation of this study is the nature of the administrative data source, which contained information about paid
claims only. Any diagnosis, procedure, or medication dispensing that occurred and was not recorded or that was paid
out-of-pocket was not included in this study. Additionally, we
assumed that dispensed medications were actually taken as
prescribed by members, and in this analysis we did not assess
adherence to dispensed medications.
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Sixth, members choosing to participate in this diabetes
incentive program could have been more motivated in managing their health and thus utilized more health care resources.
As with any observational study, the lack of randomization
allows for the presence, and influence, of biases that we have
not identified. Seventh, we chose to include only patients who
were utilizing antidiabetic medications. Our results may have
differed if we also included patients who were identified as
having diabetes but not yet utilizing pharmacotherapy for the
condition.
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Appendix

ICD-9-CM and CPT Codes Applied in Determining Process-of-Care Rates and Comorbiditiesa

A1c (CPT)
83036, 83037
Asthma (ICD-9-CM)
493.XX
COPD (ICD-9-CM)
491.XX, 492.XX, 496
Coronary artery disease (ICD-9-CM)
410.XX - 414.XX
Diabetes mellitus (ICD-9-CM)
250.XX, 357.2, 362.0X, 366.41, 648.0X
Eye examinationb (CPT/ICD-9-CM)
CPT: 67028, 67030, 67031, 67036, 67038-67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220,
67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 92230, 92235, 92240, 92250, 92260
ICD-09-CM: 14.1-14.5, 14.9, 95.02-95.04, 95.11, 95.12, 95.16
HDL-C (CPT)c
80061, 83700, 83701, 83704, 83718
Heart failure (ICD-9-CM)
398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428.XX
LDL-C (CPT)
80061, 83700, 83701, 83704, 83721
Medical attention for nephropathyd (CPT/ICD-9-CM)
81000-81003, 81005, 82042, 82043, 82044, 84156, 36145, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365,
50370, 50380, 90920, 90921, 90924, 90925, 90935, 90937, 90939, 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512
ICD-9-CM: 250.4, 403, 404, 405.01, 405.11, 405.91, 580-588, 753.0, 753.1, 791.0, V42.0, V45.1, V56, 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95,
54.98, 55.4-55.6
Mental health diagnoses (ICD-9-CM)e
293.XX, 294.XX, 295.XX, 296.XX, 297.XX, 298.XX, 299.XX
Polycystic ovary syndrome (ICD-9-CM)
256.4
aCode

sets based upon HEDIS specifications except where noted.20
code list also includes codes for eye procedures as a proxy for dilated eye exam.
cHDL-C testing is not a HEDIS measure.
dCodes include a range of procedures that indicate provider attention to renal function per HEDIS specifications.
eIncludes code sets for psychosis, schizophrenia, depression, and paranoia.
A1c = hemoglobin A1c; COPD = chronic obstructive pulmonary disease; CPT = Current Procedural Terminology; HDL-C = high-density lipoprotein cholesterol;
HEDIS = Healthcare Effectiveness Data and Information Set; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; LDL-C = lowdensity lipoprotein cholesterol.
b CPT
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